ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients
详细信息 查看全文
- 作者：Sinead Cuffea ; b ; scuffe@stjames.ie" class="auth_mail" title="E-mail the corresponding author ; Abul Kalam Azada ; Xiaoping Qiua ; Xin Qiuc ; Yonathan Brhanec ; Qin Kuanga ; Sharon Marshd ; Sevtap Savasa ; e ; Zhuo Chena ; Dangxiao Chenga ; Natasha B. Leighla ; Glenwood Gossf ; Scott A. Laurief ; Lesley Seymourg ; Penelope A. Bradburya ; g ; Frances A. Shepherda ; Ming Sound Tsaoh ; Bingshu E. Cheng ; Wei Xuc ; Geoffrey Liua
- 关键词：NSCLC ; non-small cell lung cancer ; ABC ; adenosine triphosphate-binding cassette ; NCIC CTG ; NCIC Clinical Trials Group ; OS ; overall survival ; HWE ; Hardy&ndash ; Weinberg equilibrium ; 95% CI ; 95% confidence intervals ; aHR ; adjusted Hazard Ratios
- 刊名：Cancer Epidemiology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：41
- 期：Complete
- 页码：50-56
- 全文大小：553 K
文摘
- •
ABCC2 is upregulated in NSCLC and has been implicated in platinum resistance.
- •
A allele of ABCC2 4544G > A was linked to adverse survival among 170 NSCLC patients.
- •
This result was validated among 219 NSCLC patients from the BR.24 clinical trial.